Literature DB >> 21477159

A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate.

Toshio Kitawaki, Norimitsu Kadowaki, Keiko Fukunaga, Yasunari Kasai, Taira Maekawa, Katsuyuki Ohmori, Takashige Kondo, Ryuji Maekawa, Masashi Takahara, Mie Nieda, Kiyotaka Kuzushima, Takayuki Ishikawa, Takashi Uchiyama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21477159     DOI： 10.1111/j.1365-2141.2010.08490.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  12 in total

Review 1.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Authors:  Ann Van Driessche; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-01-30

Review 2.  Haematological malignancies: at the forefront of immunotherapeutic innovation.

Authors:  Pavan Bachireddy; Ute E Burkhardt; Mohini Rajasagi; Catherine J Wu
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

Review 3.  The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?

Authors:  Domenico Galati; Serena Zanotta; Marialuisa Bocchino; Rosaria De Filippi; Antonio Pinto
Journal:  Cancer Immunol Immunother       Date:  2021-01-01       Impact factor: 6.968

Review 4.  Wilms' Tumor 1 (WT1): The Vaccine for Cancer.

Authors:  Kyaw Zaw Hein; Shuyang Yao; Siqing Fu
Journal:  J Immunother Precis Oncol       Date:  2020-11-12

Review 5.  Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?

Authors:  Kordelia Barbullushi; Nicolò Rampi; Fabio Serpenti; Mariarita Sciumè; Sonia Fabris; Pasquale De Roberto; Nicola Stefano Fracchiolla
Journal:  Cancers (Basel)       Date:  2022-06-17       Impact factor: 6.575

Review 6.  Developing strategies in the immunotherapy of leukemias.

Authors:  Jason B Brayer; Javier Pinilla-Ibarz
Journal:  Cancer Control       Date:  2013-01       Impact factor: 3.302

Review 7.  DC-based immunotherapy for hematological malignancies.

Authors:  Toshio Kitawaki
Journal:  Int J Hematol       Date:  2013-12-31       Impact factor: 2.490

Review 8.  Recent advance in antigen-specific immunotherapy for acute myeloid leukemia.

Authors:  Norimitsu Kadowaki; Toshio Kitawaki
Journal:  Clin Dev Immunol       Date:  2011-10-19

9.  Zoledronate-pulsed dendritic cell-based anticancer vaccines.

Authors:  Takashi Kamigaki; Masashi Takahara; Ryuji Maekawa; Shigenori Goto
Journal:  Oncoimmunology       Date:  2013-07-09       Impact factor: 8.110

Review 10.  Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy.

Authors:  Heleen H Van Acker; Sébastien Anguille; Viggo F Van Tendeloo; Eva Lion
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.